Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016

Monica E. Patton, MD; David Stephens, MD; Kelly Moore, MD; Jessica R. MacNeil, MPH


Morbidity and Mortality Weekly Report. 2017;66(19):509-513. 

In This Article

Abstract and Introduction


Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10–25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.)[1] and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.).[2] In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A),[3] and in June 2015, ACIP recommended that adolescents and young adults aged 16–23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B).[4] Consistent with the original Food and Drug Administration (FDA) licensure for the two available MenB vaccines, ACIP recommended either a 3-dose series of MenB-FHbp or a 2-dose series of MenB-4C. Either MenB vaccine can be used when indicated; ACIP does not state a product preference. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses in a series. In April 2016, changes to the dosage and administration of MenB-FHbp were approved by FDA to allow for both a 2-dose series (administered at 0 and 6 months) and a 3-dose series (administered at 0, 1–2, and 6 months).[5,6] In addition, the package insert now states that the choice of dosing schedule depends on the patient's risk for exposure and susceptibility to serogroup B meningococcal disease. These recommendations are regarding use of the 2- and 3-dose schedules of MenB-FHbp vaccine (Trumenba) and replace previous ACIP recommendations for use of MenB-FHbp vaccine published in 2015.[3,4] Recommendations regarding use of MenB-4C (Bexsero) are unchanged.[3,4]

*Persons with persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5–C9, properdin, factor D, factor H, or who are taking eculizumab [Solaris]); persons with anatomic or functional asplenia (including sickle cell disease); microbiologists routinely exposed to isolates of Neisseria meningitidis; persons identified as at increased risk because of a serogroup B meningococcal disease outbreak.
Category A recommendations are made for all persons in an age- or risk-factor-based group. Category B recommendations are made for individual clinical decision making. https://www.cdc.gov/vaccines/acip/recs/grade/about-grade.html.